IDEX Corporation' Total Glaucoma Solution Campaign For US Market To Debut At Annual Congress Of The American Society of Cataract & Refractive Surgery
MOUNTAIN VIEW, Calif., April 16, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) today announced the debut of its Total Glaucoma Solution, a commercial offering for the US market focused on the Company's growing portfolio of glaucoma products. The recent introduction of the Cyclo G6 system and its family of disposable probes combined with the versatile IQ 532 laser for MicroPulse Laser Trabeculoplasty (MLT), together represent a more complete solution for comprehensive and specialty glaucoma practices.
"Today there exists a gap in glaucoma care - the gap is between glaucoma medications that are costly and result in poor patient compliance and invasive surgery with its higher risk profile," stated Will Moore, IRIDEX President and CEO. "A durable, cost-effective solution to bridge this gap continues to be our focus and a goal of global healthcare systems as they seek to advance the trend toward value-based medicine."
Glaucoma is the leading cause of adult irreversible blindness. It is estimated that about 4 million people in the US and approximately 60 million worldwide are afflicted with glaucoma today.
"The MicroPulse P3 disposable has become an essential part of my armamentarium for use in glaucoma surgical procedures. It provides a safe and efficacious solution for IOP control," stated glaucoma and cataract specialist Robert J. Noecker, MD, MBA of the Ophthalmic Consultants of Connecticut. "I have used MicroPulse P3 for some of my most complicated cases, but also I feel comfortable enough using it for patients with earlier disease in which we want to avoid a filtering bleb or the placement of hardware in the eye."
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning potential applications for the Company products, changes in the Company's product portfolio, changes in share value, the protectability and results of any future challenges to the Company's intellectual property rights, the markets in which the Company operates, trends in treatment and product usage, demand for the Company's products, product plans and future product releases, regulatory approvals, usage and efficacy of Company products, future financial results and the Company's strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in the Company's Annual Report on Form 10-K for the fiscal year ended January 3, 2015, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/iridex-total-glaucoma-solution-campaign-for-us-market-to-debut-at-annual-congress-of-the-american-society-of-cataract-and-refractive-surgery-300066858.html
SOURCE IRIDEX Corporation